Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048984 · ClinicalTrials.gov registry record
Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma
A clinical trial of Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, sponsored by Children's Oncology Group.
- Completed
- Registry status
- 637
- Enrollment target
- 1
- Study location
NCT00048984: Completed study of Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, sponsored by Children's Oncology Group.
NCT00048984 is a study of Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor that has completed, run by Children's Oncology Group. The registered enrollment target is 637 participants, above the 67-participant average among 6 other Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor trials with a reported enrollment target (851% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00048984, a study of Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- 637 participants
- Enrollment target
- 1
- Study location
Study Summary
Diagnostic trial to study genetic differences in patients who have Ewing's sarcoma. Genetic testing may help predict how cancer will respond to treatment and allow doctors to plan more effective therapy.
Primary Outcome
Univariate analysis using the proportional-hazards regression model will be used to formally assess the prognostic significance of each biological characteristic as it relates to risk for adverse event. Methods such as recursive partitioning adapted to survival analysis will be used to explore possible interactions between the presence of various markers and risk for adverse event.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 637 participants |
| Start Date | 2003-01 |
What the finished NCT00048984 record still lists
NCT00048984 is an observational study that tracks outcomes without assigning an intervention. The registered 637 participants enrollment target is mid-sized for trials with a published cap, above the 67-participant average among 6 other Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor trials with a reported enrollment target (851% higher).
The record links to 3 conditions, with Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor appearing as the primary indexed condition, and to 1 intervention - of which laboratory biomarker analysis is the first listed.
NCT00048984 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00048984 about?
NCT00048984 is a clinical study titled "Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma". Diagnostic trial to study genetic differences in patients who have Ewing's sarcoma. Genetic testing may help predict how cancer will respond to treatment and allow doctors to plan more effective therapy.
What is the current status of trial NCT00048984?
This trial is currently completed. The enrollment target is 637 participants. The study started on 2003-01.
What conditions does trial NCT00048984 study?
This clinical trial studies the following conditions: Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor.
What interventions are being tested in trial NCT00048984?
The interventions under investigation include: laboratory biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT00048984?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00048984 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
COMPLETED · Phase 1
-
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
COMPLETED · Phase 2
-
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821129 · 636 participants · NA
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
- NCT03478826 · 635 participants
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
- NCT04339699 · 640 participants · NA
NobleStitch EL STITCH Trial is a PFO Comparative Trial
- NCT04979338 · 640 participants · Phase 3
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia